Managing Schizophrenia in a Patient With Alcohol Abuse and Hepatic Impairment CME/CE

Author Information and Disclosures

Release Date: April 30, 2008; Valid for credit through April 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 nursing contact hours (1.0 contact hours are in the area of pharmacology);
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Janssen, Ortho-McNeil
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Recognize how comorbid disorders involving drugs or alcohol affect the pharmacologic treatment of schizophrenia
  2. Examine the importance of considering pharmacologic profiles and routes of metabolism when selecting an antipsychotic therapy in schizophrenia with comorbid substance abuse
  3. Demonstrate how to overcome the most common barriers to the successful treatment of a schizophrenia patient with concomitant alcohol-related liver impairment
Authors and Disclosures

John Kane, MD
Disclosure: John Kane, MD, has disclosed that he has served as an advisor or consultant for Abbott, Bristol-Myers Squibb, Janssen, Pfizer, and Lilly.


Lynne K. Schneider, PhD
Disclosure: Lynne K. Schneider, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the American Council on Pharmacy Education (461-000-08-013-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.